<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01821040</url>
  </required_header>
  <id_info>
    <org_study_id>LOD3501</org_study_id>
    <secondary_id>2011-002353-57</secondary_id>
    <nct_id>NCT01821040</nct_id>
  </id_info>
  <brief_title>A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR</brief_title>
  <official_title>A Randomised, Multi-centre, Double-blind, Active-controlled, Parallel Group Study to Assess the Efficacy and Safety of Modified Release Prednisone (Lodotra®) Compared to Immediate Release Prednisone (Prednisone IR) in Subjects Suffering From Polymyalgia Rheumatica (PMR).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mundipharma Research Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mundipharma Research Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study compares the efficacy and safety of modified release prednisone versus immediate&#xD;
      release prednisone in patients suffering from polymyalgia rheumatica.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of a screening phase, followed by a 4 week double-blind phase. During the&#xD;
      double-blind phase, the patients will be randomised in a 1:1 ratio to either Lodotra® or&#xD;
      immediate release prednisone (prednisone IR) plus respective placebo.&#xD;
&#xD;
      After completion of the double-blind phase, patients will be re-randomised in a 1:1 ratio to&#xD;
      open-label Lodotra® or prednisone IR for 48 weeks. During the open-label phase, the dose of&#xD;
      study medication will be tapered based on titration criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To show that treatment with Lodotra® is noninferior to treatment with prednisone IR with regards to the percentage of complete responders.</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Polymyalgia Rheumatica</condition>
  <arm_group>
    <arm_group_label>Lodotra®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lodotra, starting dose of 15mg administered in the evening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisone IR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisone IR 15mg daily start dose (immediate release) administered in the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lodotra®</intervention_name>
    <description>Lodotra, starting dose of 15mg administered in the evening</description>
    <arm_group_label>Lodotra®</arm_group_label>
    <other_name>Modified release prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone IR (immediate release)</intervention_name>
    <description>Prednisone IR 15mg daily start dose (immediate release) administered in the morning,</description>
    <arm_group_label>Prednisone IR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females, 50 years of age or older who provided written informed consent.&#xD;
&#xD;
          2. Females less than one year post-menopausal must have a negative serum or urine&#xD;
             pregnancy test recorded prior to the first dose of study medication, be non-lactating,&#xD;
             and willing to use adequate and highly effective methods of contraception throughout&#xD;
             the study. A highly effective method of birth control is defined as those which result&#xD;
             in a low failure rate (i.e. less than 1% per year) when used consistently and&#xD;
             correctly such as sterilisation, implants, injectables, combined oral contraceptives,&#xD;
             some IUDs (Intrauterine Device, hormonal), sexual abstinence or vasectomised partner).&#xD;
&#xD;
          3. Subjects newly diagnosed with polymyalgia rheumatica and previously untreated with&#xD;
             glucocorticoids for PMR. The diagnosis of polymyalgia rheumatica must be confirmed by&#xD;
             all of the following criteria:&#xD;
&#xD;
               -  New onset bilateral shoulder pain or new onset bilateral shoulder and hip girdle&#xD;
                  pain.&#xD;
&#xD;
               -  PMR VAS score over the last 24 hours before the Screening Visit ≥ 50 (on a 0 -&#xD;
                  100 scale).&#xD;
&#xD;
               -  Morning stiffness duration of ≥ 45 min on the day before the Screening Visit.&#xD;
&#xD;
               -  Acute phase response shown by elevated C-reactive protein (CRP; ≥ 2 times ULN).&#xD;
&#xD;
          4. Subjects willing and able to participate in all aspects of the study and comply with&#xD;
             the use of study medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Females who are pregnant (positive β-hCG test) or lactating.&#xD;
&#xD;
          2. Subjects with any contraindication/history of hypersensitivity to predniso(lo)ne or&#xD;
             other ingredients.&#xD;
&#xD;
          3. Significant renal impairment (serume creatinine &gt; 150 µmol/L).&#xD;
&#xD;
          4. Significant hepatic impairment (ALT, AST and GGT &gt; 2.5 ULN).&#xD;
&#xD;
          5. Subjects suffering from another disease which requires glucocorticosteroid treatment.&#xD;
             Topical glucocorticosteroids, e.g. intra-nasal or inhaled glucocorticosteroids are&#xD;
             allowed but should be kept at a stable dose throughout the study.&#xD;
&#xD;
          6. Continued use of systemic glucocorticoids within 4 weeks prior to the Screening Visit.&#xD;
&#xD;
          7. Joint injections with glucocorticoids within 6 weeks prior to the Screening Visit.&#xD;
&#xD;
          8. Subjects who require treatment with non-permitted concomitant therapies.&#xD;
&#xD;
          9. Evidence of clinically significant cardiovascular, renal, hepatic, gastrointestinal or&#xD;
             psychiatric disease at the time of screening, as determined by medical history,&#xD;
             clinical laboratory tests, ECG results, and physical examination, that would place the&#xD;
             subject at risk upon exposure to the study medication or that may confound the&#xD;
             analysis and/or interpretation of the study results.&#xD;
&#xD;
         10. Active alcohol or drug abuse.&#xD;
&#xD;
         11. Subjects suffering from giant cell arteritis, late onset rheumatoid arthritis or other&#xD;
             inflammatory rheumatoid diseases.&#xD;
&#xD;
         12. Subjects suffering from drug-induced myalgia.&#xD;
&#xD;
         13. Subjects suffering from fibromyalgia&#xD;
&#xD;
         14. Subjects suffering from systemic lupus erythemathosus.&#xD;
&#xD;
         15. Subjects suffering from neurological conditions, e.g. Parkinson's disease.&#xD;
&#xD;
         16. Subjects suffering from active cancer.&#xD;
&#xD;
         17. Subjects suffering from an active infection.&#xD;
&#xD;
         18. Subjects who participated in a clinical research study involving a new chemical entity&#xD;
             or an experimental drug within 30 days prior to the Screening Visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Southend University Hospital</name>
      <address>
        <city>Westcliff on Sea</city>
        <zip>SS9 9RY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/search?query=LOD3501</url>
    <description>Link to Results</description>
  </link>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>March 14, 2013</study_first_submitted>
  <study_first_submitted_qc>March 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2013</study_first_posted>
  <last_update_submitted>October 22, 2018</last_update_submitted>
  <last_update_submitted_qc>October 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polymyalgia rheumatica</keyword>
  <keyword>PMR</keyword>
  <keyword>Modified release prednisone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

